UNIVERSITY of PENNSYLVANIA PATENT LICENSE AGREEMENTPatent License Agreement • August 10th, 2010 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • Pennsylvania
This Patent License Agreement (this “Agreement”) is between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Aegerion Pharmaceuticals, Inc, a Delaware corporation (“Company”). This Agreement is effective on May 19, 2006 (the “Effective Date”).
SUBLEASE AGREEMENTSublease Agreement • August 10th, 2010 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
This lease between GLB 3 LLC, a New Jersey limited liability company (herein Landlord), and Tibbett & Britten Group North America, Inc., a Delaware corporation (herein Tenant), is dated for reference purposes only as of this 28th day of April, 2004.
AMENDED AND RESTATED WARRANT AGREEMENT To Purchase Shares of the Series A Preferred Stock of Aegerion Pharmaceuticals, Inc. Dated as of September 29, 2008 (the “Effective Date”)Warrant Agreement • August 10th, 2010 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
WHEREAS, Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Senior Loan and Security Agreement, dated as of March 30, 2007 (the “Loan Agreement”) with Hercules Technology Growth Capital, Inc., a Maryland corporation (the “Warrantholder”);
NEITHER THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR ASSIGNED IN THE...Aegerion Pharmaceuticals, Inc. • August 10th, 2010 • Pharmaceutical preparations • Delaware
THIS NOTE IS SUBJECT TO A THIRD AMENDED AND RESTATED SUBORDINATION AGREEMENT DATED JUNE 14, 2010 BETWEEN THE COMPANY AND HERCULES TECHNOLOGY GROWTH CAPITAL, INC., A COPY OF WHICH MAY BE OBTAINED UPON WRITTEN REQUEST FROM THE COMPANY.
LICENSE AGREEMENTLicense Agreement • August 10th, 2010 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
The following patent applications shall also be treated as “Bayer Patent Rights” under this Agreement, provided that any of the following patent applications may have lapsed, may have been cancelled, or are otherwise no longer still pending as of the Effective Date:
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • August 10th, 2010 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS LOAN AND SECURITY AGREEMENT is made and dated as of March 20, 2007 and is entered into by and between AEGERION PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), with its chief executive office and principal place of business located at 1140 Route 22 East, Suite 304, Bridgewater, NJ 08807 and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation (“Lender”), with its principal place of business located at 400 Hamilton Avenue, Palo Alto, CA 94301.
AEGERION PHARMACEUTICALS, INC. THIRD AMENDED AND RESTATED NOTE PURCHASE AGREEMENT June 14, 2010Note Purchase Agreement • August 10th, 2010 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS THIRD AMENDED AND RESTATED NOTE PURCHASE AGREEMENT (the “Agreement”) is made as of June 14, 2010 (the “Effective Date”) by and among Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the persons and entities named on the Schedule of Purchasers attached hereto as Schedule I (individually, a “Purchaser” and collectively, the “Purchasers”).
AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • August 10th, 2010 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT is made as of November 9, 2007 (“Investor Rights Agreement”), by and among Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors listed on Schedule I attached hereto (the “Investors”).
SECURED PROMISSORY NOTEAegerion Pharmaceuticals, Inc. • August 10th, 2010 • Pharmaceutical preparations
This Promissory Note is the Note referred to in, and is executed and delivered in connection with, that certain Loan and Security Agreement dated March 20,2007, by and between Borrower and Lender (as the same may from time to time be amended, modified or supplemented in accordance with its terms, the “Loan Agreement”), and is entitled to the benefit and security of the Loan Agreement and the other Loan Documents (as defined in the Loan Agreement), to which reference is made for a statement of all of the terms and conditions thereof. All payments shall be made in accordance with the Loan Agreement. All terms defined in the Loan Agreement shall have the same definitions when used herein, unless otherwise defined herein. An Event of Default under the Loan Agreement shall constitute a default under this Promissory Note. Reference to the Loan Agreement shall not affect or impair the absolute and unconditional obligation of the Borrowers to pay all principal and interest and premium, if any,
